Navigation Links
Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
Date:9/1/2011

SAN DIEGO, Sept. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the following investor conferences:

  • R.W. Baird Health Care Conference on Wednesday, September 7, 2011 at 12:45 p.m. Eastern Time at the New York Palace in New York.
  • Morgan Stanley Global Healthcare Unplugged Conference on Tuesday, September 13, 2011 at 8:00 a.m. Eastern Time at the Grand Hyatt in New York.
  • UBS Global Life Sciences Conference on Monday, September 19, 2011 at 12:00 p.m. Eastern Time at the Grand Hyatt in New York.
  • JMP Securities Healthcare Conference on Tuesday, September 27, 2011 at 4:00 p.m. Eastern Time at the St. Regis in New York.

Live audio webcasts of these presentations will be accessible on the Investors page of the Company's website at www.optimerpharma.com.  Replays of these presentations will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has developed and is commercializing DIFICID™ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Contacts

Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-909-0736

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
3. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
4. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
5. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
6. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
7. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
8. Optimer Pharmaceuticals Expands Senior Management Team
9. Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
10. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
11. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Massachusetts , May 26, 2016 ... (NGS) has matured into an essential life science tool ... and development applications. BCC Research reveals in its new ... a second growth phase, one powered by a range ... fields.      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 ... bedient dringenden Bedarf zur ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur Entwicklung ... zu sein. Ein erstes Projekt wird die Entwicklung ...
(Date:5/25/2016)... May 25, 2016  According to Kalorama Information, the ... in 2015.  Though these are challenging times in ... for success for companies that remain optimistic and ... new growth prospects medical device companies spend a ... development (R&D) than do companies in other industries.  ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac ... significant negative impact on long-term patient survival, reports a team of UPMC researchers ... this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical information ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma Solutions, the leading ... health and global clinical supply services, today announced two key appointments and the ... investment and strategic growth plans in the Asia Pacific region. , Howard Kim ...
(Date:5/26/2016)... ... ... In an effort to provide hair restoration information to the widest possible audience, Dr. Parsa ... not use the app. Dr. Mohebi, the founder of Parsa Mohebi Hair Restoration, is making ... , Dr. Mohebi says, “The positive response to the Snapchat videos we started last month ...
(Date:5/26/2016)... Wash. (PRWEB) , ... May 26, 2016 , ... ... trusted provider of comprehensive treatment for eating disorders, is opening a brand new ... will provide individuals ages 8-17 and their families with even more specialized eating ...
(Date:5/26/2016)... ... May 26, 2016 , ... Nike Yoga Camps at ... daily practices, arts & crafts, discussions, and games all geared towards enhancing your ... have combined backgrounds in kids’ yoga, collegiate sport yoga instruction, and global yoga ...
Breaking Medicine News(10 mins):